ArticleJournal of the American Chemical Society2026
Siderophore-Pt(IV) Conjugates as Tools to Probe Cytoplasmic Cargo Delivery to Gram-Negative Bacteria.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Elucidating the uptake pathways and cellular localization of bacterial siderophores is important for establishing a fundamental understanding of Fe homeostasis and trafficking. Discerning the same for nonnative siderophores is a key consideration in the translational development of siderophore-antibiotic conjugates for "Trojan-horse" drug delivery. Here, we employ the native triscatecholate siderophore enterobactin (Ent) or its synthetic mimic TRENCAM (TC) conjugated to a Pt(IV) prodrug based on cisplatin to study the localization of these siderophores within various Gram-negative bacteria. The Pt(IV) warhead, which is reductively activated upon delivery to the cytoplasm, targets DNA and provides the readout of filamentous morphology, repurposing the anticancer drug as a probe for bacterial cytoplasmic delivery. By applying TC-Pt(IV) as a delivery probe, we establish that uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.